<DOC>
	<DOCNO>NCT01257204</DOCNO>
	<brief_summary>To identify short duration antiviral therapy ( 12 16 week ) combination daclatasvir pegylated interferon alfa-2a ribavirin .</brief_summary>
	<brief_title>Study Genotype 2 3 Patients With Chronic Hepatitis Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Participants chronically infect hepatitis C virus ( HCV ) genotype 2 3 No previous exposure interferon formulation ( ie , interferon alfa , pegylated interferon alfa2a ) ribavirin Body mass index ( BMI ) 18 35 kg/m^2 , inclusive . BMI=weight ( kg ) /height ( ) ^2 Males female , 18 70 year age Key Liver transplant recipient Documented suspected hepatocellular carcinoma Evidence decompensated cirrhosis History chronic hepatitis B virus ( HBV ) . Patients resolve HBV infection may participate Current known history cancer Any gastrointestinal disease surgical procedure may impact absorption study drug Inability tolerate oral medication Poor venous access Severe psychiatric disease History chronic pulmonary disease History cardiomyopathy , coronary artery disease ( include angina ) , interventive procedure coronary artery disease ( include angioplasty , stent procedure , cardiac bypass surgery ) , ventricular arrhythmia , , clinically significant cardiac disease History current electrocardiogram finding indicative cardiovascular instability Preexisting ophthalmologic disorder consider clinically significant eye History uncontrolled diabetes mellitus Any known contraindication pegylated interferon alfa2a ribavirin otherwise specify . Positive hepatitis B virus surface antigen , HIV1 HIV2 Ab Prior exposure HCV direct antiviral agent ( eg , HCV protease , polymerase , previous nonstructural protein 5A inhibitor ) Exposure investigational drug placebo</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>